Valeant says can contain hit to dermatology, projects 2016 growth

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. UNH
7. TMUS
8. SPY
9. CVS
10. SBUX

Go back to Valeant says can contain hit to dermatology, projects 2016 growth

Upward Earnings Revisions to Drive Valeant (VRX) Higher - Guggenheim

December 17, 2015 7:13 AM EST

Guggenheim analyst Louise Chen reiterated a Buy rating and $195 price target on Valeant Pharmaceuticals (NYSE: VRX) following yesterday's analyst day. The analyst thinks upwards consensus earnings revisions and multiple expansion will drive VRX shares higher

Chen commented, "Post VRX's Investor Day on 12/16/15, we think upwards... More